The regulation of myeloid cell responses can determine tumor outcomes.
In this issue of Immunity, Blidner et al.
report that galectin-1 triggers both immunoregulatory and pro-angiogenic circuits in myeloid cells, promoting tumor growth via a VEGF-dependent mechanism.
